Grants for For profit organizations other than small businesses - Science and Technology

This funding opportunity supports various organizations in Maine to develop and implement projects that expand affordable housing options and workforce housing through community planning and collaboration.

This funding opportunity supports research projects that use genome editing techniques to explore the genetic factors contributing to substance use disorders, encouraging diverse organizations to participate in advancing addiction science.

The Equip Harlingen grant program, offered by the Harlingen Economic Development Corporation (EDC), is a small business matching grant designed to provide financial assistance of up to $3,000 for new equipment purchases. This program is rooted in the EDC's mission to foster economic development within the City of Harlingen. By supporting businesses in expanding their production capabilities, the grant directly aligns with the foundation's strategic priority of stimulating economic activity and promoting job retention and creation. The underlying theory of change is that direct investment in local businesses' operational capacity will lead to increased production, sales, and ultimately, a more robust local economy with sustained employment opportunities. The primary target beneficiaries of the Equip Harlingen grant are for-profit commercial businesses located within the city limits of Harlingen, TX. Specifically, the program targets businesses that have been operational for at least one full year, occupy commercial space, and have fewer than 20 employees. This focus aims to bolster the small to medium-sized business sector, which is often a significant driver of local economies. National chains or franchises with more than three locations, and establishments with more than two locations, are explicitly excluded to ensure the benefits are concentrated on local, independent businesses. The program's core priorities and focuses revolve around supporting businesses in increasing production, expanding operations, and generating more sales through the acquisition of new equipment. Eligible expenses are strictly defined as new equipment under warranty that will directly enable these growth objectives, such as stoves, ovens, lathes, and tooling machines. The emphasis is on equipment that is essential for the creation of more products, indicating a clear focus on manufacturing, culinary, and other production-oriented businesses. The expected outcomes of the Equip Harlingen grant include the retention and creation of jobs within business enterprises in the City of Harlingen, leading to further economic stimulation. Measurable results are tied to the financial assistance provided, which is 50% of incurred equipment costs, not exceeding $3,000. While not explicitly stated as metrics, the program's success would likely be measured by the number of businesses supported, the direct increase in production capacity reported by recipients, and ultimately, the impact on local employment figures and sales tax generation. The requirement for applicants to generate local sales taxes reinforces the program's aim to contribute to the city's overall economic health.

This grant provides $1 million to a qualified nonprofit or educational institution in California to develop a project aimed at improving health outcomes and reducing disparities for low-income and marginalized communities in San Diego and Imperial Counties.

This grant provides funding to established and early-career biomedical researchers in Arizona to advance innovative health research that improves healthcare outcomes and stimulates the local economy.

This program provides matching funds to Nebraska businesses collaborating with local colleges or universities on research and development projects that create or improve products and processes to boost revenue.

This funding opportunity provides financial support to medical examiner and coroner offices for accreditation and to develop forensic pathology fellowships, addressing workforce shortages and improving death investigation standards nationwide.

This grant provides funding and resources to early-stage ag-tech businesses in Kentucky to develop and market innovative solutions that enhance the agricultural industry.

This funding opportunity supports a variety of organizations in California to develop and implement safer, sustainable pest management practices that protect public health and the environment while promoting economic vitality.

The anticipated funding opportunity announcement (FOA) aims to support research and development projects under the Vehicle Technologies Office (VTO). The goals include the demonstration of smart charge management for electric vehicles, improvement of 12-volt lead-acid batteries for safety-critical electric vehicle applications, development of strategies to reduce the likelihood of cascading effects of electric vehicle fires, reduction in battery electrode, cell, and pack manufacturing costs, advancement of silicon-based anodes for lithium-ion batteries, and development of high-energy density conversion cathodes. The FOA emphasizes advancing equity, addressing the climate crisis, and achieving net-zero emissions by 2050. Eligible applicants are encouraged to include underrepresented groups and underserved communities in their project teams. The FOA will fund activities related to electric vehicle (EV) technologies, focusing on areas such as smart charge management, safety improvements in EV batteries, cost reduction in battery manufacturing, and the development of advanced battery materials. The Department of Energy aims to drive innovation in clean energy technologies, ensuring environmental justice and inclusion. Specific areas of interest include wide-scale demonstrations of smart charge management, enhancement of safety-critical 12-volt lead-acid batteries, reduction of cascading effects of battery fires, cost reduction in battery manufacturing, and the development of high-energy-density battery components.

The COVID-19 Relief – Supporting Elm and Main (SEAM) program will provide financial assistance to the community revitalization organizations dedicated to community and economic development in older and historic downtowns, commercial districts, and neighborhoods according to the principles of the Elm Street and Main Street Approaches. The program, supported by Keystone Communities funding, is intended to assist Elm Street and Main Street organizations that have been economically impacted by COVID-19. Financial Info: The COVID-19 Relief – Supporting Elm and Main (SEAM) program will provide financial assistance to the community revitalization organizations dedicated to community and economic development in older and historic downtowns, commercial districts, and neighborhoods according to the principles of the Elm Street and Main Street Approaches. The program, supported by Keystone Communities funding, is intended to assist Elm Street and Main Street organizations that have been economically impacted by COVID-19.

This program provides financial assistance to small business and commercial property owners in Jackson, Mississippi, to improve the appearance of their buildings and attract more customers and investors.

This grant provides funding for researchers to conduct innovative studies on ovarian cancer, focusing on impactful solutions that benefit patients and their families.

This funding opportunity provides financial support for projects that conserve and improve natural resources, targeting municipalities, nonprofits, schools, and private property owners in Hennepin County.

The ARP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of ASD. Applications are strongly encouraged to address one of the FY24 ARP Clinical Trial Award Areas of Interest. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.Research funded by the FY24 ARP should be responsive to the needs of people with ASD, their families, and/or caregivers. Researchers are therefore encouraged to establish and utilize effective collaborations and partnerships with community members to maximize the impact potential of the proposed research.CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in womens health outcomes and/or advancing knowledge for womens health.

This initiative provides financial support to early-stage climate technology startups in Massachusetts to help them develop their innovations and achieve commercial success in the clean energy sector.

This grant invites local organizations in the Atchison community to become partner agencies, enabling them to collaborate with the Atchison Area United Way to enhance community support and participate in fundraising efforts.

The FY24 PCRP Exploration Hypothesis Development Award supports the exploration of highly innovative, untested, potentially high-gain concepts, theories, paradigms, and/or methods that address an important problem relevant to one or more of the FY24 PCRP Overarching Challenges. This award is designed to provide investigators the opportunity to pursue serendipitous observations that may reveal entirely new avenues for investigation. Results of studies conducted through this award may provide the scientific premise upon which a new hypothesis can be based or initial proof of principle of an innovative hypothesis, laying the groundwork for future avenues of scientific investigation. Presentation of preliminary data is inconsistent with the intent of this award mechanism and is therefore strongly discouraged. However, logical reasoning and a sound scientific rationale for the proposed work must be described. Reviewers will be blinded to the identity of the Principal Investigator (PI), collaborator(s), and their organization(s). Refer to Section II.D.2.b.i, Full Application Submission Type, for more information. New for FY24: Clinical research is allowed. For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes: (1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies. (2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. (3) Outcomes research and health services research that do not fit under the definition of clinical trial. Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule. Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials. A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 PCRP priorities. Innovative research involving nuclear medicine and related techniques to support early diagnosis, more-effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies. Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/ journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. The funding instrument for awards made under the program announcement will be grants (31 USC 6304). The anticipated direct costs budgeted for the entire period of performance for an FY24 Exploration Hypothesis Development Award should not exceed $150,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. Awards supported with FY24 funds will be made no later than September 30, 2025. The CDMRP expects to allot approximately $3.60M to fund approximately 15 Exploration Hypothesis Development Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030. Research Involving Animals: All research funded by the FY24 PCRP Exploration-Hypothesis Development Award involving new and ongoing research with animals must be reviewed and approved by the USAMRDC Office of Human and Animal Research Oversight (OHARO; previously the Human Research Protection Office), Animal Care and Use Review Office (ACURO), in addition to the local Institutional Animal Care and Use Committee (IACUC) of record. IACUC approval at the time of submission is not required. Allow at least 3 to 4 months for ACURO regulatory review and approval processes for animal studies. Refer to the General Application Instructions for additional information.

This grant provides funding to various organizations to expand career education and training in allied health occupations for adults from disadvantaged backgrounds and healthcare workers facing advancement barriers.

To obtain a copy of the Funding Opportunity Announcement (FOA) please go to the ARPA-E website at https://arpa-e-foa.energy.gov. To apply to this FOA, Applicants must register with and submit application materials through ARPA-E eXCHANGE (https://arpa-e-foa.energy.gov/Registration.aspx). For detailed guidance on using ARPA-E eXCHANGE, please refer to the ARPA-E eXCHANGE User Guide (https://arpa-e-foa.energy.gov/Manuals.aspx). ARPA-E will not review or consider concept papers submitted through other means. For problems with ARPA-E eXCHANGE, email ExchangeHelp@hq.doe.gov (with FOA name and number in the subject line). Questions about this FOA? Check the Frequently Asked Questions available at http://arpa-e.energy.gov/faq. For questions that have not already been answered, email ARPA-E-CO@hq.doe.gov. The purpose of this modification is to incorporate changes to Funding Opportunity Announcement. Accordingly, this modification: Inserted new Exploratory Topic, Topic M: H2SENSE. See Table 1. Exploratory Topics, Appendix M, and Total Amounts to be awarded on Cover Page. Updated Language in Appendix L Section 5.